{"status": "OK", "response": {"docs": [{"type_of_material": "Op-Ed", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "Money is vital in combating the global AIDS epidemic, but diplomacy is key as well. Many lives hang in the balance as the world's trade ministers debate allowing poor countries continued access to cheap generic drugs. Last month, officials left a meeting in Tokyo without resolving the issue, and the stalemate has continued at talks in Geneva. President Bush's request for an additional $10 billion over the next five years to fight AIDS in Africa is great news, but the money will go much farther if poor countries can get affordable drugs. This is the problem: Patent rules adopted by the World Trade Organization in 1996 and set to come into effect gradually over the next decade will limit trade of generic drugs that compete with patented products.", "headline": {"main": "The New AIDS Fight; Generic Drugs Can Make the Money Last"}, "abstract": "World Bank managing director Mamphela Ramphele and chief economist Nicholas Stern Op-Ed article maintains diplomacy is one of keys to combating global AIDS epidemic; notes poorer countries that cannot manufacture their own drugs could be barred from importing generic versions; drawing (M)", "print_page": "19", "word_count": 663, "_id": "4fd2706e8eb7c8105d82c0f9", "snippet": "Money is vital in combating the global AIDS epidemic, but diplomacy is key as well. Many lives hang in the balance as the world's trade ministers debate allowing poor countries continued access to cheap generic drugs. Last month, officials left a...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/03/01/opinion/the-new-aids-fight-generic-drugs-can-make-the-money-last.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "INTERNATIONAL BANK FOR RECONSTRUCTION AND DEVELOPMENT"}, {"name": "subject", "value": "GENERIC AND BRAND NAME PRODUCTS"}, {"name": "subject", "value": "ACQUIRED IMMUNE DEFICIENCY SYNDROME"}, {"name": "subject", "value": "INTERNATIONAL TRADE AND WORLD MARKET"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "BUDGETS AND BUDGETING"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Mamphela", "lastname": "Ramphele"}, {"organization": "", "role": "reported", "rank": 2, "firstname": "Nicholas", "lastname": "Stern"}], "original": "By Mamphela Ramphele and Nicholas Stern"}, "document_type": "article", "pub_date": "2003-03-01T00:00:00Z", "section_name": "Health; Opinion"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "A senior executive at Bayer testified in court yesterday that company officials in the United States recommended against selling the anticholesterol drug Baycol several years before it was introduced in 1997 because they thought its sales potential was limited. But Baycol was introduced because officials in Germany, where Bayer is based, decided to push ahead when market conditions improved and the potential for profit looked promising for many years.", "headline": {"main": "Bayer Official Offers Defense In Texas Trial Of Drug Suit"}, "abstract": "Bayer executive Lawrence Posner tells Texas court that company officials in US recommended against selling anticholesterol drug Baycol several years before it was introduced in 1997, because they doubted sales potential; Bayer's German executives pushed marketing until drug was withdrawn in 2001 after more than 30 deaths were linked to it; Posner testifies in suit by Hollis Haltom, 82, who contracted muscle disorder rhabdomyolysis after taking Baycol (M)", "print_page": "1", "word_count": 1300, "_id": "4fd241c48eb7c8105d7da3ec", "snippet": "A senior executive at Bayer testified in court yesterday that company officials in the United States recommended against selling the anticholesterol drug Baycol several years before it was introduced in 1997 because they thought its sales potential...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/03/01/business/bayer-official-offers-defense-in-texas-trial-of-drug-suit.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "POSNER, LAWRENCE"}, {"name": "persons", "value": "HALTOM, HOLLIS"}, {"name": "organizations", "value": "BAYER AG"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "BAYCOL (DRUG)"}, {"name": "subject", "value": "RHABDOMYOLYSIS (MUSCLE DISEASE)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MUSCLES"}, {"name": "subject", "value": "CHOLESTEROL"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Melody", "lastname": "PETERSEN"}], "original": "By MELODY PETERSEN"}, "document_type": "article", "pub_date": "2003-03-01T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 2, "offset": 0, "time": 27}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}